{"id":"W4388816741","doi":"10.1016/j.jocn.2023.11.013","title":"Efficacy and safety of iscalimab, a novel anti-CD40 monoclonal antibody, in moderate-to-severe myasthenia gravis: A phase 2 randomized study","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Neuroscience","topic":"Myasthenia Gravis and Thymoma","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"ca_institutions":"Université Laval; Montreal Neurological Institute and Hospital","funders":"Novartis Institutes for BioMedical Research; Novartis Pharmaceuticals Corporation","keywords":"Medicine; Myasthenia gravis; Monoclonal antibody; Antibody; Internal medicine; Immunology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006759111,0.0002282157,0.002095178,0.0004879199,0.00007998881,0.00004662081,0.0003525205,0.00009156746,0.0000172891],"category_scores_gemma":[0.006242694,0.0001541294,0.0003743607,0.001195576,0.000458444,0.0001816678,0.0001866792,0.0006623339,0.000006438553],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001038951,"about_ca_system_score_gemma":0.0002833677,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001341367,"about_ca_topic_score_gemma":0.000002534357,"domain_scores_codex":[0.994979,0.0004566981,0.002783917,0.0004773279,0.0009289825,0.000374104],"domain_scores_gemma":[0.9965083,0.00162659,0.0007838927,0.000320152,0.0002527041,0.0005083646],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.6475339,0.02221439,0.1910632,0.0001384493,0.0001851871,0.002920803,0.001866058,0.001523778,0.1194428,0.000357015,0.0003530692,0.01240135],"study_design_scores_gemma":[0.4072263,0.005601376,0.5681688,0.0003926945,0.0001847682,0.0005698649,0.0001911446,0.01683176,0.0001698739,0.0001819793,0.0002878311,0.0001936995],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9957392,0.00004244881,0.001057879,0.001559953,0.0004749952,0.001031722,0.00001643013,0.00001608977,0.00006134785],"genre_scores_gemma":[0.9981796,0.0002447095,0.000659016,0.0006562461,0.0001358678,0.000004399959,0.000001109724,0.00002053269,0.0000985757],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3771055,"threshold_uncertainty_score":0.7473539,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08698101969012068,"score_gpt":0.4553612079200692,"score_spread":0.3683801882299485,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}